ADNP syndrome

Lore & Background

ADNP syndrome was first identified in 2014, though the ADNP gene itself was cloned in 1998. The syndrome results from non-inherited loss-of-function mutations in the ADNP gene, which produces a protein involved in chromatin remodeling and regulation of gene expression critical for brain development. Most mutations are stop-gain or frameshift, often leading to a truncated protein. The condition is not typically inherited, though a very small risk of germline mosaicism exists.

Reader's Guide

ADNP syndrome is significant as a recently identified but relatively common single-gene cause of autism spectrum disorder, with over 275 children registered by June 2022. Its hallmark features include severe speech and motor delay, intellectual disability (ranging from mild to severe), characteristic facial features, and autistic traits. Almost all affected children experience speech delay, with first words appearing on average at 30 months. The syndrome also involves a broad spectrum of comorbidities such as seizures, sleep disturbance, feeding issues, visual dysfunction, and cardiac anomalies. Diagnosis is established through genetic testing, and treatment is symptomatic, including therapies and early behavioral interventions. Research into potential treatments includes a Phase 2A clinical trial suggesting low-dose ketamine may be effective, and the peptide drug davunetide (NAP) has shown neuroprotective effects in preclinical trials. The syndrome also displays an inverse comorbidity with cancer, where equivalent mutations may lead to developmental delay or cancer depending on timing.

Did You Know?

• The average age for first words in children with ADNP syndrome is 30 months, with a range of 7 to 72 months.
• Loss of previously acquired skills was reported in one fifth of children with ADNP syndrome.
• A Phase 2A clinical trial suggested that low-dose ketamine may be effective in treating clinical symptoms in children with ADNP syndrome.

The Clinical Portrait

ADNP syndrome presents as a broad neurodevelopmental condition whose core features include intellectual disability, global developmental and motor planning delays, and autistic or autism-spectrum traits. Nearly every affected child experiences significant speech delay; the average age for producing a first word sits around thirty months, though the observed range stretches from seven to seventy-two months, and a small number of individuals never develop functional language. Intellectual disability spans a wide spectrum, from mild—seen in roughly one child in eight—to severe, which accounts for approximately half of those studied. Most children also display characteristic facial traits, including a prominent forehead, high hairline, a wide and depressed nasal bridge, and a short nose with a full, upturned tip. Hypotonia, behavioral challenges, sleep disruption, seizures, feeding difficulties, and gastrointestinal problems are frequently reported. Notably, during the infant and toddler years, many children are described as having a remarkably cheerful and happy disposition. While autism-spectrum features are common, the socializing difficulties tend to be less severe than those typically seen in other ASD diagnoses. Loss of previously acquired skills has been documented in about one-fifth of children, and toilet training is delayed in most.

Genetic Architecture and Molecular Role

ADNP syndrome arises from de novo, non-inherited mutations in the ADNP gene, a roughly forty-kilobase stretch of DNA located at chromosomal position 20q13.13. The protein encoded by this gene plays a central role in chromatin remodeling—the process by which the packaging of DNA and associated proteins is adjusted to modulate how tightly genetic material is wound, thereby regulating the expression of downstream genes. Because the ADNP protein is especially critical for controlling genes that drive normal brain development, and likely influences genes governing other organ systems as well, its disruption produces the wide-ranging neurological and physical manifestations seen in the syndrome. To date, only loss-of-function variants—such as stop-gain or frameshift mutations—have been directly linked to the condition, most of which generate a truncated, nonfunctional protein. Recurrence risk for siblings is very low when neither parent carries the variant, though a small possibility of germline mosaicism in either parent means the risk is never absolutely zero. Intriguingly, research has revealed an inverse comorbidity relationship: the same class of ADNP mutations can predispose toward neurodevelopmental disorder or toward cancer, depending on whether the mutation is present from the very start of development. The gene's involvement in the autophagy pathway, also implicated in schizophrenia, remains an active area of investigation as of 2023.

Diagnosis and the Treatment Landscape

Confirming ADNP syndrome requires identifying a pathogenic variant in the ADNP gene through molecular genetic testing. In practice, a child presenting with developmental delay typically undergoes chromosomal microarray analysis first. If that does not yield a diagnosis, the next step is usually a multigene panel or whole-exome sequencing. When the clinical picture strongly suggests ADNP syndrome, targeted single-gene testing—sequence analysis followed by deletion and duplication analysis of the ADNP locus—may be pursued directly. Because no cure currently exists, management is symptomatic and multidisciplinary. Speech therapy, occupational therapy, physical therapy, and individualized educational programs form the backbone of care, while early behavioral interventions aim to build self-care, social, and language skills. Additional support may address neuropsychiatric symptoms, nutritional needs, ophthalmologic findings, and cardiac or urinary anomalies. On the research front, a 2020 Phase 2A clinical trial conducted at the Seaver Autism Center of Mount Sinai Hospital indicated that low-dose ketamine could be effective in alleviating certain clinical symptoms in affected children. Separately, davunetide (NAP), a peptide derived from the ADNP protein itself, has demonstrated neuroprotective effects in preclinical studies and is being explored as a potential therapeutic candidate.

From Discovery to Community

Although the ADNP gene was first cloned in 1998, the syndrome itself was not formally described until 2014, when researchers connected specific mutations to a recognizable clinical picture. The condition is also known by the eponymous name Helsmoortel-Van der Aa syndrome (HVDAS). Despite its relatively recent identification, ADNP syndrome is projected to become one of the most common single-gene causes of autism spectrum disorder, a distinction that underscores both its clinical significance and the urgency of building a dedicated research infrastructure. The community response has been swift: by June 2022, the ADNP Kids Research Foundation Contact Registry had enrolled just over 275 children, creating a vital cohort for ongoing studies. A landmark moment came on November 3, 2019, when the first ADNP Syndrome Family Conference and Scientific Symposium was held on the UCLA campus in Los Angeles, California, bringing together families, clinicians, and researchers for the first time in a dedicated forum. This gathering marked a turning point, transforming ADNP syndrome from a scattered collection of individual diagnoses into a recognized, named condition with its own scientific and advocacy ecosystem.

Gallery